Sparrow BioAcoustics Announces the Launch of Stethophone™ – Bringing the Future of Personalized Heart Care Closer to Home

Stethophone™ by Sparrow BioAcoustics

Sparrow BioAcoustics [Sparrow], a pioneer in the field of bioacoustics technology, announces the launch of Stethophone™, a groundbreaking advancement in personalized heart health, exclusively on Valentine’s Day, February 14, 2024. This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location.

Built-in Microphone

Stethophone works by harnessing the built-in microphone of a smartphone to capture the nuanced sounds of the heart. Through sophisticated bioacoustics engineering, these sounds are then filtered to provide clear, medical-grade diagnostic signals – some of them at the outermost edges of human auditory perception. With widespread adoption, it is anticipated that this bioacoustics technology will allow for the detection and diagnosis of routine and difficult cardiac conditions sooner and with more ease.

FDA Clearance

An an unprecedented move, Stethophone recently won FDA clearance in 2023 for use by medical professionals in the United States, marking it as the first-ever FDA-cleared smartphone stethoscope Software-as-a-Medical-Device (SaMD). Furthermore, the software has achieved another landmark by obtaining FDA clearance, again in 2023, for use by consumers – another first in the industry – empowering individuals to take an active role in their heart health.

In addition to providing the sophisticated bioacoustics technology that powers Stethophone, Sparrow offers medical practitioners advanced visualizations that enable them to understand how to interpret the diagnostics originating from the device. These visualizations aid in the recognition of patterns and anomalies that may not be easily discernible by conventional cardiac diagnostics, thereby potentially enhancing today’s diagnostic accuracy and efficiency.

Mark Attila Opauzsky, CEO of Sparrow BioAcoustics

“We are at the forefront of a revolution in personalized heart health. Stethophone embodies our commitment to provide everyone the power, agency and access to fight heart disease right in their own hands. Launching on Valentine’s Day symbolizes our dedication to heart health and the love and care we invest in our products and the people they serve.” Valentine’s Day also marks the five-year anniversary when Mark almost lost his life to a sudden, rare disease. To him, this launch is very personal.

Future

As Sparrow eagerly celebrates the release of Stethophone, the company is already looking toward the future with the development of the next iteration of Stethophone, which explores integrating artificial intelligence functionalities into the bioacoustics engineering.

Stethophone is available now on iOS. To learn more about Stethophone and Sparrow BioAcoustics, please visit https://stethophone.com/.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.